OBJECTIVE	To assess the efficacy and safety , and determine the optimal dosage , of a once-daily ( OD ) formulation of the clinically uroselective alpha ( 1 ) - blocker , alfuzosin , in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia .\